Arriello Welcomes New Additions
to the Drug Safety & Regulatory Teams.
Arriello is thrilled to announce the addition of two seasoned professionals to our team, each bringing a wealth of expertise to strengthen our Global Drug Safety and Regulatory Affairs capabilities.
Neda Zmajević joins Arriello as Global Drug Safety Associate Director.
Neda brings over 20 years of pharmacovigilance and pharmaceutical management experience, blending strategic and operational roles across the industry. In her dual role, she not only ensures alignment with client standards as Associate Director but also supports the medical team as a Safety Physician.
Known for her problem-solving approach, Neda’s experience includes providing medical assessments and expert opinions, as well as leading teams through complex projects. Her background in pharmacovigilance, marketing, clinical research, and consulting has honed her leadership skills and dedication to quality outcomes.
Rebecca Tregent joins us as Director of Regulatory Affairs.
With over a decade of experience in Global Regulatory Affairs, Rebecca has an impressive track record in guiding a wide range of therapies through early-phase drug and medical device development. Her expertise spans Phase I-III Clinical Trials, eCTDs, INDs/NDAs, unlicensed medicines, and Expanded Access Programs (EAPs).
Having worked extensively on novel drugs, medical devices, and combination therapies, she offers clients a deep understanding of regulatory strategies and pathways.
Rebecca’s unique background as both a clinical trial scientist and Health Authority regulator enables her to bridge perspectives, enhancing success and efficiency for our clients.
We are excited to welcome Neda and Rebecca to Arriello, as their expertise and leadership will be instrumental in driving our commitment to regulatory and drug safety excellence.
Neda will report into Sam Tomlinson, our VP of Global Drug Safety and Rebecca into Kate Coleman, our VP Regulatory, Quality & Compliance (Principal Consultant).
Latest News:
